How Can Physician-Led Medication Reviews Benefit Severely Mentally Ill Diabetic Patients?

Summary:

In patients with severe mental disorder and diabetes, physician-led medication reviews
significantly reduced the number of prescribed drugs and potentially inappropriate prescriptions (PIPs) compared to usual care without structured medication reviews, though it was associated with no additional costs, indicating cost-neutrality.

Clinical Context

Patients with severe mental disorders such as schizophrenia, bipolar disorder, and treatment-resistant depression face substantially higher rates of diabetes and other cardiometabolic conditions compared to the general population. This elevated risk stems from multiple factors including antipsychotic medication effects on weight and glucose metabolism, lifestyle factors associated with chronic mental illness, and barriers to accessing and engaging with healthcare. These patients commonly receive complex medication regimens spanning psychiatric and medical domains, creating significant potential for polypharmacy, drug interactions, and inappropriate prescriptions. Fragmented care between psychiatric and primary care services often results in medication accumulation without systematic review. The concept of potentially inappropriate prescriptions (PIPs) encompasses medications that carry risks outweighing benefits in specific patient contexts or that lack clear indication. Physician-led medication reviews represent a systematic approach to evaluating entire medication regimens with the goal of optimizing therapy and reducing harm from unnecessary or inappropriate medications.

Clinical Pearls

• Physician-led medication reviews successfully reduced both total medication count and potentially inappropriate prescriptions in patients with severe mental disorders and diabetes.
• The intervention achieved medication optimization without increasing healthcare costs, demonstrating cost-neutrality that supports implementation feasibility.
• Patients with dual psychiatric and metabolic comorbidity represent a particularly high-yield population for medication review given their complex regimens and elevated polypharmacy risk.
• Structured medication review provides a mechanism for bridging psychiatric and medical care, addressing a gap common in fragmented healthcare systems.

Practical Application

Healthcare systems serving patients with severe mental illness should implement structured medication review programs, recognizing that this population faces exceptional polypharmacy risk. Psychiatrists, primary care physicians, and clinical pharmacists can collaborate to conduct comprehensive reviews that address both psychiatric and medical medications. The cost-neutrality finding removes financial barriers to program implementation from a health system perspective. For individual clinicians, periodic medication reconciliation with explicit attention to potentially inappropriate prescriptions should become standard practice for this patient population. When discontinuing medications, gradual tapering with monitoring for destabilization is essential, particularly for psychiatric medications. The goal is not simply medication reduction but optimization of the regimen to maximize benefit while minimizing harm.

Broader Evidence Context

Medication review interventions have demonstrated benefits across various populations including nursing home residents and elderly patients with polypharmacy. This study extends the evidence to patients with severe mental disorders and comorbid diabetes, a population underrepresented in prior deprescribing research. The cost-minimization analysis approach appropriately addresses health system concerns about resource allocation for quality improvement interventions. The findings align with professional society recommendations for periodic medication review in complex patients and support integration of deprescribing principles into psychiatric practice. The success in this challenging population suggests that systematic medication review can be beneficial even when patient engagement and adherence are complicated by mental illness.

Study Limitations

• Clinical outcomes such as adverse events, hospitalizations, and mortality were not reported, limiting assessment of whether medication reduction translated to health benefits.
• Sample size and specific characteristics of the patient population were not detailed in the summary.
• The specific methodology for identifying potentially inappropriate prescriptions was not described.
• Whether medication reductions were sustained over time and whether patients remained clinically stable after deprescribing was not addressed.
• The intervention required physician time and expertise that may not be available in all healthcare settings.

Bottom Line

Physician-led medication reviews reduce total medications and potentially inappropriate prescriptions in patients with severe mental disorders and diabetes without increasing healthcare costs. Healthcare systems should implement structured medication review programs for this high-risk population to optimize prescribing and reduce polypharmacy-related harm.

Source: Christensen, Johan Frederik Mebus Meyer, et al. “Facilitating the Implementation of Physician-Led Medication Reviews for Patients With Severe Mental Disorder and Diabetes: A Cost-Minimization Analysis.” Read article here.